Konu "Non-small cell lung cancer" için TF, Dahili Tıp Bilimleri Bölümü Koleksiyonu listeleme
Toplam kayıt 6, listelenen: 1-6
-
Cisplatin-based chemotherapy in elderly patients with advanced stage (IIIB and IV) non-small cell lung cancer patients
(SAP - Slovak Academic Press, spol. s.r.o., 2011)Lung cancer continues to be the leading cause of cancer-related mortality and approximately 70% of patients present with locally advanced or metastatic disease at the time of diagnosis. More than 50% of lung cancer cases ... -
Contribution of metabolic tumor volume and total lesion glycolysis to predict prognosis in early-stage lung cancer at preoperative staging
(Coll Physicians & Surgeons Pakistan, 2022)Objective: To evaluate the effect of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) values of the primary tumor measured by preoperative positron emission tomography/computed tomography (FDG-PET/CT) on ... -
Do volume-based and metabolic 18F FDG PET/CT parameters identify groups at risk for poor prognosis in patients with newly diagnosed metastatic and non-metastatic non-small cell lung cancer?
(Akad Doktorlar Yayinevi, 2020)To determine the relationship between F-18 FDG PET/CT parameters of the primary tumor/nodal metastasis/distant metastasis and overall survival (OS) of patients with newly diagnosed non-small cell lung cancer (NSCLC). Data ... -
Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine
(2012)Limited data exist concerning the long-term (?5 year) survival rates of patients with stage IIIB and IV non-small cell lung carcinoma (NSCLC) receiving chemotherapy. We aimed to determine the long-term results of cisplatin ... -
Necrosis on pre-radiotherapy F-18-FDG PET/CT is a predictor for complete metabolic response in patients with non-small cell lung cancer
(Lippincott Williams & Wilkins, 2022)To investigate necrosis on pre-radiotherapy (RT) F-18-FDG PET/CT (PETNECROSIS) as a predictor of complete metabolic response (CMR) in patients with non-small cell lung cancer (NSCLC). We evaluated patients with inoperable ... -
Necrosis onstaging 18F FDG PET/CT is associated with worse progression-free survival in patients with stage IIIB non-small cell lung cancer
(Wolters Kluwer Medknow Publications, 2022)Objective: The presence of pathological necrosis in the tumor is known to be a factor indicating worse survival. Our study defined necrosis in staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography ...